FDA Classifies Abiomed Automated Impella Controller Recall as Class I: Purge Flag Failure Triggers Phased Global Withdrawal

Published 2026-10-02 13:30 · Recalls and Safety Alerts

What Happened

On September 24, 2026, the U.S. Food and Drug Administration (FDA) updated its recall communication and formally classified the Abiomed Automated Impella Controller (AIC) recall as a Class I recall — the most serious category FDA assigns. FDA states on its page that Abiomed has issued letters to affected customers recommending that all Automated Impella Controllers be removed from sites where they are in use or offered for sale. While awaiting on-site service from Abiomed, hospitals may continue to use their existing inventory to maintain continuity of therapy.

Affected Products and Identification Information

The recall covers three controller configurations packaged for the U.S. market:

• Impella Controller (product number 0042-0000-US, UDI-DI 00813502010022)
• Impella Optical Controller (0042-0010-US, UDI-DI 00813502010985)
• Optical, AIC, Impella Controller (0042-0040-US, UDI-DI 00813502011401)

FDA explicitly states that all AICs worldwide are within the scope of this withdrawal. Abiomed is therefore executing a phased withdrawal strategy rather than a single comprehensive recovery. The controller serves as the primary user interface for the Impella catheter, controlling catheter performance, monitoring alarms and displaying information on the catheter's position at the aortic valve.

Failure Mode

The recall stems from failure of the purge flag component within the purge pressure sensor assembly. This component engages with the purge disc so that the controller can recognize whether the purge disc has been correctly inserted. When the component fails, users see a Purge Disc Disconnected alarm during procedure preparation, or a Purge Disc Not Detected alarm during hemodynamic support. According to the instructions for use, the first step is to reinsert the purge disc to clear the alarm; if the alarm persists, the Automated Impella Controller should be replaced with a backup unit. FDA notes that each such failure requires controller replacement to resolve.

Risks

If the failure occurs before support is initiated, the procedure may be delayed; in patients with unstable hemodynamics, such a delay may mean a period without mechanical circulatory support. If it occurs during Impella support, it typically arises during a planned purge cassette change, but it can also occur during ongoing support; in that case, purge delivery stops while mechanical circulatory support continues, and a controller replacement must be arranged. According to FDA's page, as of August 17, Abiomed had reported 37 serious injuries and 3 deaths associated with this problem.

Corrective Actions

Abiomed's corrective pathway is replacement of the purge flag and purge retainer within the purge pressure sensor assembly, performed either through annual preventive maintenance or through separate contact by the field service team. Customers should also clean the controller housing with a mild detergent as specified, to avoid damaging plastic components — including the purge flag — through improper cleaning, and should perform routine annual preventive maintenance on the controller in accordance with the instructions for use. According to FDA's page, Abiomed notified all affected customers on August 12, asking them to forward the notice to personnel within their facility responsible for managing, transporting, storing, stocking and using the devices, to post it in a prominent location, and to notify any recipient to whom the device has been transferred.

Timeline

FDA's timeline shows that the agency had previously issued an early alert on this issue and subsequently, on September 24, 2026, updated the communication to a Class I recall. The event is recorded in FDA's system under Event ID 99671, which can be used to search the FDA medical device recall database.

Sources and Applicability

Source: U.S. Food and Drug Administration (FDA), Medical Device Recalls and Early Alerts page, Heart Pump Controller Recall: Abiomed Removes Automated Impella Controllers, published and updated September 24, 2026. https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/heart-pump-controller-recall-abiomed-removes-automated-impella-controllers

FDA Enforcement Report (Event ID 99671). https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=99671

Verification scope and access date: this article reviewed the FDA recall/early alert page referenced above, including its timeline and affected product table, and cross-checked the FDA CDRH New — News and Updates listing; the access date was October 2, 2026. Product numbers and UDI-DIs are taken from the information listed on the official page.

Applicability note: this article is an interpretation of publicly available FDA regulatory information and does not constitute a conclusion or commitment regarding any specific product, company or registration application. The injury and death figures, dates and product scope referenced herein are subject to the official text; information may change with subsequent official updates. Companies should rely on the most recent notices from FDA and the manufacturer when handling inventory or deciding whether to continue use.

Information sources

• U.S. Food and Drug Administration (FDA) — Heart Pump Controller Recall: Abiomed Removes Automated Impella Controllers, 2026-09-24
• U.S. Food and Drug Administration (FDA) — Enforcement Report (Event ID 99671)
• U.S. Food and Drug Administration (FDA) — CDRH New: News and Updates

AIMEILI Regulatory Interpretation

Class I Designation Reflects a Reasonable Probability of Serious Adverse Health Consequences

A Class I recall is not a procedural label; it is FDA's determination that use of the affected device may cause serious adverse health consequences or death. In this case the agency has tied the designation to 37 serious injuries and 3 deaths reported as of August 17, and to a failure mode that can interrupt purge delivery during circulatory support. For regulatory affairs teams, the practical consequence is that this is a high-visibility enforcement action: correspondence, corrective action documentation and inventory reconciliation will be examined closely during any subsequent inspection.

Phased Withdrawal Requires Documented Inventory Traceability

Because Abiomed is withdrawing all AICs globally in phases rather than through a single recall sweep, the withdrawal is executed over an extended period. That places the burden of traceability on the distribution chain. Organizations should reconcile their records against the three affected product numbers and UDI-DIs listed above, and maintain evidence of unit-level status — in use, quarantined, returned or awaiting field service — throughout the transition.

Continued Use Provisions Must Be Controlled, Not Informal

FDA states that hospital inventory may remain in use while awaiting Abiomed service. This is a controlled allowance, not a general release from the recall. Facilities should have a written procedure covering the alarm response sequence — reinsert the purge disc first, and replace the controller with a backup unit if the alarm does not clear — plus steps for documenting each event and arranging replacement. Bedside staff, biomedical engineering and the service provider should be working from the same documented protocol.

Field Correction Mechanics and Prevention

The corrective action — replacing the purge flag and purge retainer in the purge pressure sensor assembly through annual preventive maintenance or a separate field service visit — is a field correction tied to a defined service interval. Manufacturers and their service partners should ensure that preventive maintenance schedules are being executed, that service records are retained as objective evidence, and that cleaning instructions for the controller housing are followed with the specified mild detergent only, since improper cleaning agents can damage plastic components including the purge flag.

Communication Obligations Are Explicit

Abiomed notified affected customers on August 12 and asked them to forward the notice internally, post it prominently, and notify downstream recipients of transferred devices. Similar dissemination obligations apply under most jurisdictions' recall frameworks, notably U.S. 21 CFR Part 806 and, for markets outside the U.S., the vigilance and field safety corrective action requirements of the applicable regulatory system. Distributors that have shipped units onward should confirm that their own customers received the notice.

Business Impact

• Inventory and logistics pressure: A global phased withdrawal of every AIC in scope consumes field service capacity and creates a queue for replacement and retrofitting. Distributors and hospital supply chains should anticipate extended turnaround times and plan for interim substitution of backup controllers.
• Service continuity risk: Because continued use is permitted pending service, hospitals must maintain backup controller availability at each Impella-capable site. Sites unable to source a backup unit face a genuine continuity-of-therapy risk for patients on mechanical circulatory support.
• Commercial exposure: Recalls of this severity can affect tender qualifications, purchasing decisions and hospital procurement scoring, particularly in markets where a Class I equivalent designation is publicly recorded.
• Post-market surveillance and CAPA linkage: Complaint data associated with purge flag failures should feed into the manufacturer's post-market surveillance and CAPA systems, with trending sufficient to demonstrate that the field correction is effective. Regulatory authorities will expect evidence that the corrective action addressed the root cause, not only the symptom.
• Documentation readiness: Distributors and importers should be prepared to produce recall communication records, inventory reconciliation, service records and training records on request. Where the device is registered in additional jurisdictions, parallel field safety notices and reporting timelines may apply.
• Commercial partner diligence: CROs, OEM partners and regulatory affairs teams supporting Abiomed-related programs should verify whether any study protocols, investigational plans or registry activities involve AICs, and confirm that any device under investigation is handled in line with the manufacturer's field correction.